Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Finding partners through DNA profiles has yet to catch on, but the commercial sector for preconception and prenatal testing is booming. Malorye Allison Branca reports.
Mitochondrial replacement therapy is being touted as a means of combating maternally inherited disease. But concerns are growing about mitochondrial reversion compromising cures. Steve Connor investigates.
As the technology to create genetically modified babies moves closer to practice, what questions should we ask before such procedures are contemplated? Amber Dance investigates.
Several companies are now banking on bioengineered silk to create a new generation of textiles and materials...and a necktie. Laura DeFrancesco investigates.
Our personal ecosystem of microbes is shed on everything we touch and everyplace we go. Charles Schmidt reports on efforts to harness this information to improve human health and activity.
After years under the radar, RNA vaccines are finally emerging as immunotherapies to combat pandemics and cancer. But as Laura DeFrancesco reports, clinical validation remains elusive.
Despite last year's sharp decline in approvals, registrations of two RNA drugs offer a window into the current state and possible future of drug development. Looking forward, the sector seeks greater clarity on the new presidential administration's priorities and the impact of new healthcare legislation. Chris Morrison reports.
